β-carotene in HIV infection: An extended evaluation

Gregg O. Coodley, Marcia K. Coodley, Robert Lusk, Terrence R. Green, Anthony C. Bakke, David Wilson, Danny Wachenheim, Gary Sexton, Catherine Salveson

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective: Several small short-term intervention studies have suggested that β-carotene supplementation in HIV-infected patients can increase the number of various immune cells including CD4 cells. This prospective double-blinded study was designed to investigate whether β-carotene supplementation would result in this immune-enhancement in a larger number of patients over a longer time period. Methods: HIV-positive patients were randomly assigned to receive either 60 mg β-carotene orally three times daily or a matched placebo. In addition, all patients received a multivitamin supplement. Patients were evaluated at baseline, 1 month, and 3 months for T-cell quantitative subsets, natural killer cells, HIV p24 antigen, β-carotene levels, complete blood counts and chemistry batteries. Body weights and Karnofsky scores were evaluated at each visit. Results: Seventy-two patients signed informed consent forms and entered the study. Except for serum β-carotene concentration, there were no statistically significant differences (P <0.05) between the treatment (60 mg β-carotene three limes daily and multivitamins) and placebo (placebo and multivitamins) groups at baseline or after either 1 or 3 months of treatment. Discussion: Earlier studies suggesting that β-carotene supplementation increased levels of immune cells in HIV-infected patients were not replicated in this study. The addition of a multivitamin supplement to both arms of this study may have masked any difference between the two groups. However, on the basis of the results of this study, we would not recommend supplementation with high doses of β-carotene for HIV-infected patients.

Original languageEnglish (US)
Pages (from-to)967-973
Number of pages7
JournalAIDS
Volume10
Issue number9
StatePublished - 1996

Fingerprint

Carotenoids
HIV Infections
HIV
Placebos
Citrus aurantiifolia
HIV Core Protein p24
Consent Forms
Blood Cell Count
T-Lymphocyte Subsets
Natural Killer Cells
Body Weight
Therapeutics
Serum

Keywords

  • β-carotene
  • HIV infection
  • Immune function
  • Retinol
  • Vitamins

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Coodley, G. O., Coodley, M. K., Lusk, R., Green, T. R., Bakke, A. C., Wilson, D., ... Salveson, C. (1996). β-carotene in HIV infection: An extended evaluation. AIDS, 10(9), 967-973.

β-carotene in HIV infection : An extended evaluation. / Coodley, Gregg O.; Coodley, Marcia K.; Lusk, Robert; Green, Terrence R.; Bakke, Anthony C.; Wilson, David; Wachenheim, Danny; Sexton, Gary; Salveson, Catherine.

In: AIDS, Vol. 10, No. 9, 1996, p. 967-973.

Research output: Contribution to journalArticle

Coodley, GO, Coodley, MK, Lusk, R, Green, TR, Bakke, AC, Wilson, D, Wachenheim, D, Sexton, G & Salveson, C 1996, 'β-carotene in HIV infection: An extended evaluation', AIDS, vol. 10, no. 9, pp. 967-973.
Coodley GO, Coodley MK, Lusk R, Green TR, Bakke AC, Wilson D et al. β-carotene in HIV infection: An extended evaluation. AIDS. 1996;10(9):967-973.
Coodley, Gregg O. ; Coodley, Marcia K. ; Lusk, Robert ; Green, Terrence R. ; Bakke, Anthony C. ; Wilson, David ; Wachenheim, Danny ; Sexton, Gary ; Salveson, Catherine. / β-carotene in HIV infection : An extended evaluation. In: AIDS. 1996 ; Vol. 10, No. 9. pp. 967-973.
@article{b26fa96dd65148a0bd7c82fcd48c9f62,
title = "β-carotene in HIV infection: An extended evaluation",
abstract = "Objective: Several small short-term intervention studies have suggested that β-carotene supplementation in HIV-infected patients can increase the number of various immune cells including CD4 cells. This prospective double-blinded study was designed to investigate whether β-carotene supplementation would result in this immune-enhancement in a larger number of patients over a longer time period. Methods: HIV-positive patients were randomly assigned to receive either 60 mg β-carotene orally three times daily or a matched placebo. In addition, all patients received a multivitamin supplement. Patients were evaluated at baseline, 1 month, and 3 months for T-cell quantitative subsets, natural killer cells, HIV p24 antigen, β-carotene levels, complete blood counts and chemistry batteries. Body weights and Karnofsky scores were evaluated at each visit. Results: Seventy-two patients signed informed consent forms and entered the study. Except for serum β-carotene concentration, there were no statistically significant differences (P <0.05) between the treatment (60 mg β-carotene three limes daily and multivitamins) and placebo (placebo and multivitamins) groups at baseline or after either 1 or 3 months of treatment. Discussion: Earlier studies suggesting that β-carotene supplementation increased levels of immune cells in HIV-infected patients were not replicated in this study. The addition of a multivitamin supplement to both arms of this study may have masked any difference between the two groups. However, on the basis of the results of this study, we would not recommend supplementation with high doses of β-carotene for HIV-infected patients.",
keywords = "β-carotene, HIV infection, Immune function, Retinol, Vitamins",
author = "Coodley, {Gregg O.} and Coodley, {Marcia K.} and Robert Lusk and Green, {Terrence R.} and Bakke, {Anthony C.} and David Wilson and Danny Wachenheim and Gary Sexton and Catherine Salveson",
year = "1996",
language = "English (US)",
volume = "10",
pages = "967--973",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - β-carotene in HIV infection

T2 - An extended evaluation

AU - Coodley, Gregg O.

AU - Coodley, Marcia K.

AU - Lusk, Robert

AU - Green, Terrence R.

AU - Bakke, Anthony C.

AU - Wilson, David

AU - Wachenheim, Danny

AU - Sexton, Gary

AU - Salveson, Catherine

PY - 1996

Y1 - 1996

N2 - Objective: Several small short-term intervention studies have suggested that β-carotene supplementation in HIV-infected patients can increase the number of various immune cells including CD4 cells. This prospective double-blinded study was designed to investigate whether β-carotene supplementation would result in this immune-enhancement in a larger number of patients over a longer time period. Methods: HIV-positive patients were randomly assigned to receive either 60 mg β-carotene orally three times daily or a matched placebo. In addition, all patients received a multivitamin supplement. Patients were evaluated at baseline, 1 month, and 3 months for T-cell quantitative subsets, natural killer cells, HIV p24 antigen, β-carotene levels, complete blood counts and chemistry batteries. Body weights and Karnofsky scores were evaluated at each visit. Results: Seventy-two patients signed informed consent forms and entered the study. Except for serum β-carotene concentration, there were no statistically significant differences (P <0.05) between the treatment (60 mg β-carotene three limes daily and multivitamins) and placebo (placebo and multivitamins) groups at baseline or after either 1 or 3 months of treatment. Discussion: Earlier studies suggesting that β-carotene supplementation increased levels of immune cells in HIV-infected patients were not replicated in this study. The addition of a multivitamin supplement to both arms of this study may have masked any difference between the two groups. However, on the basis of the results of this study, we would not recommend supplementation with high doses of β-carotene for HIV-infected patients.

AB - Objective: Several small short-term intervention studies have suggested that β-carotene supplementation in HIV-infected patients can increase the number of various immune cells including CD4 cells. This prospective double-blinded study was designed to investigate whether β-carotene supplementation would result in this immune-enhancement in a larger number of patients over a longer time period. Methods: HIV-positive patients were randomly assigned to receive either 60 mg β-carotene orally three times daily or a matched placebo. In addition, all patients received a multivitamin supplement. Patients were evaluated at baseline, 1 month, and 3 months for T-cell quantitative subsets, natural killer cells, HIV p24 antigen, β-carotene levels, complete blood counts and chemistry batteries. Body weights and Karnofsky scores were evaluated at each visit. Results: Seventy-two patients signed informed consent forms and entered the study. Except for serum β-carotene concentration, there were no statistically significant differences (P <0.05) between the treatment (60 mg β-carotene three limes daily and multivitamins) and placebo (placebo and multivitamins) groups at baseline or after either 1 or 3 months of treatment. Discussion: Earlier studies suggesting that β-carotene supplementation increased levels of immune cells in HIV-infected patients were not replicated in this study. The addition of a multivitamin supplement to both arms of this study may have masked any difference between the two groups. However, on the basis of the results of this study, we would not recommend supplementation with high doses of β-carotene for HIV-infected patients.

KW - β-carotene

KW - HIV infection

KW - Immune function

KW - Retinol

KW - Vitamins

UR - http://www.scopus.com/inward/record.url?scp=0029944085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029944085&partnerID=8YFLogxK

M3 - Article

C2 - 8853729

AN - SCOPUS:0029944085

VL - 10

SP - 967

EP - 973

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 9

ER -